Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.78 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032888 | 0.90 | TGFBR1 (0.63) | TGFBR1MAPK14MTORRIPK2KDR | |
| SCHEMBL4035145 | 0.88 | TGFBR1 (1.00) | TGFBR1MAPK14MTORRIPK2KDR | |
| SCHEMBL4033696 | 0.88 | TGFBR1 (0.61) | TGFBR1MAPK14MTORKDRPRKD1 | |
| SCHEMBL5655965 | 0.82 | TGFBR1 (0.55) | TGFBR1MAPK14MTOR | |
| SCHEMBL4030553 | 0.82 | TGFBR1 (0.67) | TGFBR1MAPK14MTORRIPK2KDR | |
| SCHEMBL4032513 | 0.80 | TGFBR1 (0.78) | TGFBR1MAPK14MTOR | |
| SCHEMBL4030048 | 0.80 | TGFBR1 (0.78) | TGFBR1MAPK14MTOR | |
| SCHEMBL4033864 | 0.78 | TGFBR1 (0.82) | TGFBR1MAPK14MTORRIPK2KDR | |
| SCHEMBL4031482 | 0.78 | TGFBR1 (0.53) | TGFBR1MAPK14MTORKDRPRKD1 | |
| SCHEMBL4035152 | 0.77 | TGFBR1 (0.49) | TGFBR1MAPK14MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| CN-1681810-A | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER PROD INC (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885MAPK14 319/4885MTOR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.